View in EDS HTML Full Text PDF Full Text

A phase 1 safety and bioimaging trial of antibody DS-8895a against EphA2 in patients with advanced or metastatic EphA2 positive cancers.

Saved in:
Bibliographic Details
Title: A phase 1 safety and bioimaging trial of antibody DS-8895a against EphA2 in patients with advanced or metastatic EphA2 positive cancers.
Authors: Gan HK; Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Melbourne, Australia. hui.gan@onjcri.org.au.; School of Cancer Medicine, La Trobe University, Melbourne, Australia. hui.gan@onjcri.org.au.; Department of Medical Oncology, Austin Health, Melbourne, Australia. hui.gan@onjcri.org.au., Parakh S; Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Melbourne, Australia.; School of Cancer Medicine, La Trobe University, Melbourne, Australia.; Department of Medical Oncology, Austin Health, Melbourne, Australia., Lee FT; Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Melbourne, Australia., Tebbutt NC; Department of Medical Oncology, Austin Health, Melbourne, Australia., Ameratunga M; Department of Medical Oncology, Austin Health, Melbourne, Australia., Lee ST; Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Melbourne, Australia.; School of Cancer Medicine, La Trobe University, Melbourne, Australia.; Department of Molecular Imaging and Therapy, Austin Health, Melbourne, Australia.; Faculty of Medicine, University of Melbourne, Melbourne, Australia., O'Keefe GJ; Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Melbourne, Australia.; Department of Molecular Imaging and Therapy, Austin Health, Melbourne, Australia., Gong SJ; Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Melbourne, Australia.; Department of Molecular Imaging and Therapy, Austin Health, Melbourne, Australia., Vanrenen C; Department of Medical Oncology, Austin Health, Melbourne, Australia., Caine J; Department of Medical Oncology, Austin Health, Melbourne, Australia., Giovannetti M; Ludwig Cancer Research, New York, NY, USA., Murone C; Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Melbourne, Australia., Scott FE; Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Melbourne, Australia.; School of Cancer Medicine, La Trobe University, Melbourne, Australia., Guo N; Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Melbourne, Australia., Burvenich IJG; Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Melbourne, Australia.; School of Cancer Medicine, La Trobe University, Melbourne, Australia., Paine C; Department of Molecular Imaging and Therapy, Austin Health, Melbourne, Australia., Macri MJ; Ludwig Cancer Research, New York, NY, USA., Kotsuma M; Daiichi Sankyo, Inc, Basking Ridge, NJ, USA., Senaldi G; Daiichi Sankyo, Inc, Basking Ridge, NJ, USA., Venhaus R; Ludwig Cancer Research, New York, NY, USA., Scott AM; Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Melbourne, Australia.; School of Cancer Medicine, La Trobe University, Melbourne, Australia.; Department of Molecular Imaging and Therapy, Austin Health, Melbourne, Australia.; Faculty of Medicine, University of Melbourne, Melbourne, Australia.
Source: Investigational new drugs [Invest New Drugs] 2022 Aug; Vol. 40 (4), pp. 747-755. Date of Electronic Publication: 2022 Apr 11.
Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Springer Country of Publication: United States NLM ID: 8309330 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-0646 (Electronic) Linking ISSN: 01676997 NLM ISO Abbreviation: Invest New Drugs Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 35404015
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: A phase 1 safety and bioimaging trial of antibody DS-8895a against EphA2 in patients with advanced or metastatic EphA2 positive cancers.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Gan+HK%22">Gan HK</searchLink>; Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Melbourne, Australia. hui.gan@onjcri.org.au.; School of Cancer Medicine, La Trobe University, Melbourne, Australia. hui.gan@onjcri.org.au.; Department of Medical Oncology, Austin Health, Melbourne, Australia. hui.gan@onjcri.org.au.<br /><searchLink fieldCode="AU" term="%22Parakh+S%22">Parakh S</searchLink>; Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Melbourne, Australia.; School of Cancer Medicine, La Trobe University, Melbourne, Australia.; Department of Medical Oncology, Austin Health, Melbourne, Australia.<br /><searchLink fieldCode="AU" term="%22Lee+FT%22">Lee FT</searchLink>; Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Melbourne, Australia.<br /><searchLink fieldCode="AU" term="%22Tebbutt+NC%22">Tebbutt NC</searchLink>; Department of Medical Oncology, Austin Health, Melbourne, Australia.<br /><searchLink fieldCode="AU" term="%22Ameratunga+M%22">Ameratunga M</searchLink>; Department of Medical Oncology, Austin Health, Melbourne, Australia.<br /><searchLink fieldCode="AU" term="%22Lee+ST%22">Lee ST</searchLink>; Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Melbourne, Australia.; School of Cancer Medicine, La Trobe University, Melbourne, Australia.; Department of Molecular Imaging and Therapy, Austin Health, Melbourne, Australia.; Faculty of Medicine, University of Melbourne, Melbourne, Australia.<br /><searchLink fieldCode="AU" term="%22O'Keefe+GJ%22">O'Keefe GJ</searchLink>; Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Melbourne, Australia.; Department of Molecular Imaging and Therapy, Austin Health, Melbourne, Australia.<br /><searchLink fieldCode="AU" term="%22Gong+SJ%22">Gong SJ</searchLink>; Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Melbourne, Australia.; Department of Molecular Imaging and Therapy, Austin Health, Melbourne, Australia.<br /><searchLink fieldCode="AU" term="%22Vanrenen+C%22">Vanrenen C</searchLink>; Department of Medical Oncology, Austin Health, Melbourne, Australia.<br /><searchLink fieldCode="AU" term="%22Caine+J%22">Caine J</searchLink>; Department of Medical Oncology, Austin Health, Melbourne, Australia.<br /><searchLink fieldCode="AU" term="%22Giovannetti+M%22">Giovannetti M</searchLink>; Ludwig Cancer Research, New York, NY, USA.<br /><searchLink fieldCode="AU" term="%22Murone+C%22">Murone C</searchLink>; Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Melbourne, Australia.<br /><searchLink fieldCode="AU" term="%22Scott+FE%22">Scott FE</searchLink>; Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Melbourne, Australia.; School of Cancer Medicine, La Trobe University, Melbourne, Australia.<br /><searchLink fieldCode="AU" term="%22Guo+N%22">Guo N</searchLink>; Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Melbourne, Australia.<br /><searchLink fieldCode="AU" term="%22Burvenich+IJG%22">Burvenich IJG</searchLink>; Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Melbourne, Australia.; School of Cancer Medicine, La Trobe University, Melbourne, Australia.<br /><searchLink fieldCode="AU" term="%22Paine+C%22">Paine C</searchLink>; Department of Molecular Imaging and Therapy, Austin Health, Melbourne, Australia.<br /><searchLink fieldCode="AU" term="%22Macri+MJ%22">Macri MJ</searchLink>; Ludwig Cancer Research, New York, NY, USA.<br /><searchLink fieldCode="AU" term="%22Kotsuma+M%22">Kotsuma M</searchLink>; Daiichi Sankyo, Inc, Basking Ridge, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Senaldi+G%22">Senaldi G</searchLink>; Daiichi Sankyo, Inc, Basking Ridge, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Venhaus+R%22">Venhaus R</searchLink>; Ludwig Cancer Research, New York, NY, USA.<br /><searchLink fieldCode="AU" term="%22Scott+AM%22">Scott AM</searchLink>; Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Melbourne, Australia.; School of Cancer Medicine, La Trobe University, Melbourne, Australia.; Department of Molecular Imaging and Therapy, Austin Health, Melbourne, Australia.; Faculty of Medicine, University of Melbourne, Melbourne, Australia.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%228309330%22">Investigational new drugs</searchLink> [Invest New Drugs] 2022 Aug; Vol. 40 (4), pp. 747-755. <i>Date of Electronic Publication: </i>2022 Apr 11.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Springer%22">Springer </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>8309330 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1573-0646 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2201676997%22">01676997 </searchLink><i>NLM ISO Abbreviation: </i>Invest New Drugs <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=35404015
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1007/s10637-022-01237-3
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 747
    Titles:
      – TitleFull: A phase 1 safety and bioimaging trial of antibody DS-8895a against EphA2 in patients with advanced or metastatic EphA2 positive cancers.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Gan HK
      – PersonEntity:
          Name:
            NameFull: Parakh S
      – PersonEntity:
          Name:
            NameFull: Lee FT
      – PersonEntity:
          Name:
            NameFull: Tebbutt NC
      – PersonEntity:
          Name:
            NameFull: Ameratunga M
      – PersonEntity:
          Name:
            NameFull: Lee ST
      – PersonEntity:
          Name:
            NameFull: O'Keefe GJ
      – PersonEntity:
          Name:
            NameFull: Gong SJ
      – PersonEntity:
          Name:
            NameFull: Vanrenen C
      – PersonEntity:
          Name:
            NameFull: Caine J
      – PersonEntity:
          Name:
            NameFull: Giovannetti M
      – PersonEntity:
          Name:
            NameFull: Murone C
      – PersonEntity:
          Name:
            NameFull: Scott FE
      – PersonEntity:
          Name:
            NameFull: Guo N
      – PersonEntity:
          Name:
            NameFull: Burvenich IJG
      – PersonEntity:
          Name:
            NameFull: Paine C
      – PersonEntity:
          Name:
            NameFull: Macri MJ
      – PersonEntity:
          Name:
            NameFull: Kotsuma M
      – PersonEntity:
          Name:
            NameFull: Senaldi G
      – PersonEntity:
          Name:
            NameFull: Venhaus R
      – PersonEntity:
          Name:
            NameFull: Scott AM
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 08
              Text: 2022 Aug
              Type: published
              Y: 2022
          Identifiers:
            – Type: issn-electronic
              Value: 1573-0646
          Numbering:
            – Type: volume
              Value: 40
            – Type: issue
              Value: 4
          Titles:
            – TitleFull: Investigational new drugs
              Type: main
ResultId 1